rs876657683
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_012144.4(DNAI1):βc.336delβ(p.Asp114ThrfsTer14) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,958 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 32)
Exomes π: 0.0000048 ( 0 hom. )
Consequence
DNAI1
NM_012144.4 frameshift
NM_012144.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.0600
Genes affected
DNAI1 (HGNC:2954): (dynein axonemal intermediate chain 1) This gene encodes a member of the dynein intermediate chain family. The encoded protein is part of the dynein complex in respiratory cilia. The inner- and outer-arm dyneins, which bridge between the doublet microtubules in axonemes, are the force-generating proteins responsible for the sliding movement in axonemes. The intermediate and light chains, thought to form the base of the dynein arm, help mediate attachment and may also participate in regulating dynein activity. Mutations in this gene result in abnormal ciliary ultrastructure and function associated with primary ciliary dyskinesia and Kartagener syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-34489393-TC-T is Pathogenic according to our data. Variant chr9-34489393-TC-T is described in ClinVar as [Pathogenic]. Clinvar id is 228334.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAI1 | NM_012144.4 | c.336del | p.Asp114ThrfsTer14 | frameshift_variant | 5/20 | ENST00000242317.9 | NP_036276.1 | |
DNAI1 | NM_001281428.2 | c.336del | p.Asp114ThrfsTer14 | frameshift_variant | 5/20 | NP_001268357.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAI1 | ENST00000242317.9 | c.336del | p.Asp114ThrfsTer14 | frameshift_variant | 5/20 | 1 | NM_012144.4 | ENSP00000242317 | ||
DNAI1 | ENST00000614641.4 | c.336del | p.Asp114ThrfsTer14 | frameshift_variant | 5/20 | 5 | ENSP00000480538 | P1 | ||
DNAI1 | ENST00000437363.5 | c.303del | p.Asp103ThrfsTer14 | frameshift_variant | 4/9 | 5 | ENSP00000395396 | |||
DNAI1 | ENST00000488369.1 | n.452del | non_coding_transcript_exon_variant | 5/9 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152122Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152122
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461836Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727218
GnomAD4 exome
AF:
AC:
7
AN:
1461836
Hom.:
Cov.:
31
AF XY:
AC XY:
3
AN XY:
727218
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152122Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74294
GnomAD4 genome
AF:
AC:
2
AN:
152122
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74294
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Primary ciliary dyskinesia Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 20, 2023 | This sequence change creates a premature translational stop signal (p.Asp114Thrfs*14) in the DNAI1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DNAI1 are known to be pathogenic (PMID: 16858015, 29363216). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with DNAI1-related conditions. ClinVar contains an entry for this variant (Variation ID: 228334). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 27, 2016 | The p.Asp114fs variant in DNAI1 has not been previously reported in individuals with primary ciliary dyskinesia or in large population studies. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 114 and leads to a premature termination codon 14 amino ac ids downstream. This alteration is then predicted to lead to a truncated or abse nt protein. Homozygous and compound heterozygous loss of function variants in D NAI1 have been well documented in individuals with primary ciliary dyskinesia ac ross several studies and are rare in individuals from large population databases . In addition, an animal model study reveals that absence of Dnaic1 in mice lead s to a reduction of mucociliary clearance resulting in chronic rhinosinusitis, which supports loss of funtion as a disease mechanism (Ostrowski 2009). In summa ry, this variant meets our criteria to be classified as pathogenic for primary c iliary dyskinesia in an autosomal recessive manner (http://www.partners.org/per sonalizedmedicine/LMM) based upon its predicted impact on the protein. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 29, 2019 | The c.336delC pathogenic mutation, located in coding exon 5 of the DNAI1 gene, results from a deletion of one nucleotide at nucleotide position 336, causing a translational frameshift with a predicted alternate stop codon (p.D114Tfs*14). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
DNAI1-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 11, 2024 | The DNAI1 c.336delC variant is predicted to result in a frameshift and premature protein termination (p.Asp114Thrfs*14). To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. Frameshift variants in DNAI1 are expected to be pathogenic. This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at